IceCure Highlights Endometriosis Cryoablation Study Results of ProSense System
Shots:
- ProSense system was used in a single-site study for 42 patients on a total of 47 lesions, published in the Journal of Vascular and Interventional Radiology. The study’s goal was to retrospectively assess the pain-free survival of symptomatic extraperitoneal endometriosis treated with percutaneous image-guided cryoablation
- The study showed that percutaneous cryoablation is a safe & effective procedure that reduces pain & obtains local control of EE. At a median follow-up of 13.5mos. after cryoablation, the efficacy rate of cryoablation to avoid secondary surgery was 92.8% per patient & 93.6% per nodule treated
- Median pain-free survival rates were 93.75% @6mos. & 82.72% after 12/24/36mos. On the visual analog scale, pain decreased from a median of 8/10 to 0/10 at the last follow-up
Ref: prnewswire | Image: IceCure
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.